Compare BRFH & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRFH | GRDX |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | 2 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 39.3M |
| IPO Year | 2010 | N/A |
| Metric | BRFH | GRDX |
|---|---|---|
| Price | $1.99 | $5.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 7.3K | ★ 132.0K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $211,467.00 | N/A |
| Revenue This Year | $115.22 | N/A |
| Revenue Next Year | $16.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 92.09 | N/A |
| 52 Week Low | $1.99 | $1.87 |
| 52 Week High | $6.08 | $6.93 |
| Indicator | BRFH | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 23.07 | 55.44 |
| Support Level | N/A | $2.16 |
| Resistance Level | $2.53 | $6.93 |
| Average True Range (ATR) | 0.14 | 0.69 |
| MACD | -0.01 | -0.20 |
| Stochastic Oscillator | 0.00 | 36.79 |
Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.